|
Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer |
Ito K, Elkin E, Blinder V, Keating N, Choudhry N |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Ito K, Elkin E, Blinder V, Keating N, Choudhry N. Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer. Cancer 2013; 119(13): 2494-502 Indexing Status Subject indexing assigned by NLM MeSH Aged; Aged, 80 and over; Antineoplastic Agents /economics /therapeutic use; Aromatase Inhibitors /economics /therapeutic use; Biomarkers, Tumor /blood; Breast Neoplasms /chemistry /drug therapy /economics /pathology; Cost Sharing /economics; Cost-Benefit Analysis; Disease Progression; Drug Costs; Female; Humans; Insurance Coverage; Markov Chains; Medicare; Medication Adherence; Neoplasm Staging; Postmenopause; Quality-Adjusted Life Years; United States AccessionNumber 22013025081 Date bibliographic record published 09/07/2013 |
|
|
|